Upcoming Events

Meet us at FASEB: Polycystic Kidney Disease – 25-30 June, Big Skye MT

Hester Bange will present a poster entitled:

3D High-Content Screening of compound libraries to identify new modulators of polycystic kidney disease

More information about the conference, click here

Past Events

SelectBio Phenotypic Screening, Cambridge, UK, 25-26 April 2017

Leo Price, OcellO’s CEO, has given a keynote lecture at the SelectBio High content and Phenotypic Screening conference, Cambridge, UK. More information about the conference, click here

Cafe Scientifique at Bishop’s Stortford College, UK 10 April 2017

Leo Price, OcellO’s founder and CEO has given a talk on stem cells in cancer at the Cafe Scientifique at Bishop’s Stortford College, at the Venue: The Leo Price Theatre, Bishop’s Stortford College, Bishop’s Stortford. UK.
What are stem cells? The commonly held view of stem cells that they follow a one-way path of development into a terminally differentiated cell in an organ has been challenged. Skin cells, for example, can be ‘reprogrammed’ back to a ‘pluripotent’ state from which they can be redirected into nerve cells or heart muscle – at least in the petri dish.  In cancer, tumour cells with stem-like properties can evade chemotherapy and allow a tumour to regrow. Specifically targeting cancer stem cells may be a strategy to overcome this kind of drug resistance. We can also exploit the properties of cancer stem cells to grow mini-tumours in the lab and use them to develop new treatments. Similarly, by growing tumours from patient biopsies, we can try to identify the most effective existing treatments for each patient – so-called personalised therapy.   Some examples of these applications will be presented.
For those that are puzzled by the venue name, it is named after Leo Price, who was headmaster at Bishop’s Stortford School from 1932-1943. He is the great uncle of the speaker.

AACR in Washington, April 1-5 2017

Leo Price or Lidia Daszkiewicz presented the following posters:

in vitro PDX models: 3D cultured patient-derived tumors for compound evaluation. 

Preclinical evaluation of MCLA-158: A bispecifıc antibody targeting LGR5 and EGFR using patient-derived colon carcinoma organoids.

Live from AACR, a video discussion on how 3D cell cultures are changing how we look at tumors

For more information on the video discussion click here

 

ELRIG-Forum 2017 in Darmstadt, Germany, 09 March 2017

Bram Herpers has given a presentation entitled:
Drug screening and profiling in patient derived cultured tissues: towards in vitro (pre)clinical trials
More information about the conference, click here

ASCO-SITC in Orlando on February 23-25

Lidia Daszkiewicz has presented a poster entitled:

A 3D image-based quantification of immune cell-tumor spheroid interactions in the presence of checkpoint inhibition

More information about the conference, click here

  • 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on November 29- December 2 2016, Munich

    OcellO showcased its latest in vitro human tumor models at booth D6.

    More information about the conference, click here

  • EACR Goodbye Flat Biology October 2016, Berlin

OcellO has won the Poster award presenting the poster entitled:

Phenotypic screening and selection of bi-specific therapeutic antibodies targeting stem cells in a panel of patient derived colon carcinoma organoids: a drug discovery program free of flat biology.

More information about the conferenceclick here

Basel Life Science Week & MipTec 2016 September 2016, Basel

OcellO has been showcasing its latest in vitro human tumor models at booth D62 and presented its work in poster and presentation abstracts:

in vitro-in vivo translation: Phenotypic screening in PDX-derived tumor spheroids cultured in ECM in 384-well plates

A 3D image-based phenotypic screen of bi-specific antibodies targeting stem cells in a panel of patient derived colon carcinoma organoids

3D High-Content Screening of compound libraries to identify modulators of Polycystic Kidney Disease

Development of a 3D Tissue Culture-Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases.

More information about the conference, click here